<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-140075" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Degenerative Myopia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Yap</surname>
            <given-names>Aaron</given-names>
          </name>
          <aff>University of Otago, Dunedin</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Meyer</surname>
            <given-names>Jay J.</given-names>
          </name>
          <aff>University of Auckland</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Aaron Yap declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jay Meyer declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>19</day>
          <month>9</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-140075.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Pathological myopia is a progressive eye condition characterized by excessive eyeball elongation, leading to biomechanical stretching of the retina, choroid, and sclera. This abnormal growth causes significant changes in ocular structures, increasing the risk of severe complications such as retinal detachment, myopic maculopathy, and choroidal neovascularization. Patients with pathological myopia may present with symptoms like scotomas, metamorphopsia, and floaters. Early detection is crucial to prevent irreversible vision loss, and management often includes optical interventions, anti-vascular endothelial growth factor therapy, or surgical treatments, depending on the severity of complications.</p>
        <p>This course enhances the participant's ability to recognize the clinical manifestations of pathological myopia, perform appropriate diagnostic evaluations, and implement timely management strategies. By collaborating with an interprofessional team&#x02014;including ophthalmologists, optometrists, and retinal specialists&#x02014;clinicians ensure comprehensive care that addresses the patient's medical and lifestyle needs. This coordinated approach improves visual outcomes and enhances the overall quality of life for individuals with pathological myopia, primarily through early intervention and tailored long-term management plans.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Differentiate between high myopia and pathological myopia using clinical examination and imaging studies.</p></list-item><list-item><p>Screen for potential complications such as retinal detachment, myopic maculopathy, and choroidal neovascularization in high-risk individuals with degenerative myopia.</p></list-item><list-item><p>Implement evidence-based management strategies, including optical interventions and pharmacologic treatments for patients with degenerative myopia.</p></list-item><list-item><p>Communicate&#x000a0;the common physical exam findings and treatment plans for degenerative myopia with the interprofessional team to enhance patient outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=140075&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=140075">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-140075.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Myopia, colloquially referred to as shortsightedness or nearsightedness, is one of the most common global eye diseases. This condition occurs when the eye's optical power is too high for the corresponding axial length of the eye, resulting in images of distant objects being focused in front of the retina. Myopia can be corrected by wearing glasses, contact lenses, or refractive surgery. However, pathologic myopia (PM) refers to a subset of ocular conditions associated with high myopia. The exact diagnostic criteria of PM have not been established. Some have defined PM based on an absolute cutoff value of refractive power (-6 to -8 D) or axial length (26.5 mm), whereas&#x000a0;others have based it on myopic maculopathy.<xref ref-type="bibr" rid="article-140075.r1">[1]</xref><xref ref-type="bibr" rid="article-140075.r2">[2]</xref></p>
      </sec>
      <sec id="article-140075.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Myopia is attributable to a complex interaction between genetics and the environment. Familial clustering in myopia is evident in results from twin studies and high sibling risk ratios.<xref ref-type="bibr" rid="article-140075.r3">[3]</xref>&#x000a0;Several genetic variants have been associated with the development of myopia. For the syndromic myopias, which include Marfan and Stickler syndrome, the implicated genes are involved in the extracellular matrix of the sclera. Gene studies have identified 25 different genetic loci in association with nonsyndromic myopia. The pathogenicity of genetic mutations is difficult to identify due to variable gene expression and interactions.<xref ref-type="bibr" rid="article-140075.r4">[4]</xref></p>
        <p>There is some evidence to suggest that spending more time&#x000a0;outdoors is protective against the development of myopia.<xref ref-type="bibr" rid="article-140075.r5">[5]</xref> Likewise, a shift towards urbanization and higher education is thought to be a significant driver of the increasing prevalence of myopia among schoolchildren.<xref ref-type="bibr" rid="article-140075.r6">[6]</xref> The predominating theory is that the increased time spent accommodating during near reading promotes signals for eye growth. Animal study results have also found the placement of both positive and negative lenses that defocus images on the retina can promote or inhibit eye growth.<xref ref-type="bibr" rid="article-140075.r7">[7]</xref><xref ref-type="bibr" rid="article-140075.r8">[8]</xref></p>
      </sec>
      <sec id="article-140075.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The prevalence of myopia varies according to ethnicity and geography. The prevalence of myopia is highest in regions of East Asia (47%) and Southeast Asia (39%) as compared to Central Europe (27%) and Central Africa (7%).<xref ref-type="bibr" rid="article-140075.r9">[9]</xref> There are also observed differences in the prevalence of myopia between urban and rural areas, which is attributed to the socioeconomic and educational systems in place.<xref ref-type="bibr" rid="article-140075.r8">[8]</xref>&#x000a0;The prevalence of pathologic myopia is reportedly from 0.9%&#x000a0;to 3.1%.<xref ref-type="bibr" rid="article-140075.r10">[10]</xref></p>
      </sec>
      <sec id="article-140075.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Myopia develops in the early to middle childhood and continues to early adulthood. Most children are born hyperopic. Then, closer to the age of 5&#x000a0;to 8, they experience a shift in their refraction through emmetropisation. After this process, the cornea stabilizes but increases in axial length, leading to progressive myopia.<xref ref-type="bibr" rid="article-140075.r11">[11]</xref>&#x000a0;In addition to longer axial lengths, individuals with pathological myopia typically manifest different ocular shapes with irregular protrusions, termed staphylomas. Excessive axial elongation stretches and thins the retina, choroid, and sclera, which results in various pathological findings&#x000a0;(see <bold>Image.</bold> Grade 3 Pathological Myopia With Diffuse Chorioretinal Atrophy).</p>
      </sec>
      <sec id="article-140075.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A complete history should&#x000a0;focus on specific ocular and systemic associations of high myopia. A review of systems focused on joint, hearing, and heart problems should be conducted to screen for an underlying connective tissue disorder. Family history and previous ocular surgery should also be elicited, paying attention to previous retinal detachments, corrective lens wear, or refractive surgery. New complaints of metamorphopsia, scotoma, flashes, and onset of new floaters suggest retinal pathology. Physical examination should begin with measuring visual acuity and intraocular pressure and assessing pupillary reaction. Next, a dilated fundal examination should be performed on the macula, optic disc, and peripheral retina. Finally, if glaucoma is suspected, an assessment of visual fields can be requested. In 2015, a specialist panel of researchers developed a universal classification system for pathological myopia (see&#x000a0;<bold>Table.</bold>&#x000a0;Pathological Myopia Categories). The Proposed Classification of Myopic Maculopathy was submitted by the Meta-Analysis for Pathologic Myopia Study Group.<xref ref-type="bibr" rid="article-140075.r2">[2]</xref>&#x000a0;</p>
        <table-wrap id="article-140075.table0" position="float" orientation="portrait">
          <caption>
            <title>Table.&#x000a0;Pathological Myopia Categories</title>
          </caption>
          <table style="height: 661px; width: 918px;" border="1" cellspacing="1" cellpadding="5">
            <tbody>
              <tr style="height: 53px;">
                <td style="width: 199.725px; height: 53px;" rowspan="1" colspan="1">Category 0</td>
                <td style="width: 693.475px; height: 53px;" rowspan="1" colspan="1">No macular lesions</td>
              </tr>
              <tr style="height: 60px;">
                <td style="width: 199.725px; height: 60px;" rowspan="1" colspan="1">&#x000a0;Category 1</td>
                <td style="width: 693.475px; height: 60px;" rowspan="1" colspan="1">
<p>Tessellated fundus</p>
<list list-type="bullet"><list-item><p>Visible choroidal vessels</p></list-item></list>
</td>
              </tr>
              <tr style="height: 60px;">
                <td style="width: 199.725px; height: 60px;" rowspan="1" colspan="1">&#x000a0;Category 2</td>
                <td style="width: 693.475px; height: 60px;" rowspan="1" colspan="1">
<p>Diffuse chorioretinal atrophy</p>
<list list-type="bullet"><list-item><p>Yellowish-white appearance to the posterior pole</p></list-item></list>
</td>
              </tr>
              <tr style="height: 60px;">
                <td style="width: 199.725px; height: 60px;" rowspan="1" colspan="1">&#x000a0;Category 3</td>
                <td style="width: 693.475px; height: 60px;" rowspan="1" colspan="1">
<p>Patchy chorioretinal atrophy</p>
<list list-type="bullet"><list-item><p>Discrete atrophic areas in the macula and peripapillary region</p></list-item></list>
</td>
              </tr>
              <tr style="height: 60px;">
                <td style="width: 199.725px; height: 60px;" rowspan="1" colspan="1">Category 4</td>
                <td style="width: 693.475px; height: 60px;" rowspan="1" colspan="1">
<p>Macular atrophy</p>
<list list-type="bullet"><list-item><p>Atrophy in the foveal region</p></list-item></list>
</td>
              </tr>
              <tr style="height: 60.0625px;">
                <td style="width: 199.725px; height: 60.0625px;" rowspan="1" colspan="1">
<p>Plus Lesions</p>
</td>
                <td style="width: 693.475px; height: 60.0625px;" rowspan="1" colspan="1">
<p>Lacquer cracks</p>
<list list-type="bullet"><list-item><p>Choroidal neovascularisation</p></list-item><list-item><p>Fuchs spots</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>
<bold>Findings</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Staphyloma is an outpouching of the wall of the eye. Posterior staphyloma is unique to pathological myopia. Posterior staphylomas associated with pathological myopia have been classified into 10 types based on shape and location.<xref ref-type="bibr" rid="article-140075.r12">[12]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Lacquer cracks are irregular yellow linear lesions in the macula. They represent mechanical linear breaks in Bruch membrane and are potential foci for choroidal neovascularisation. Newly formed lacquer cracks may be associated with bleeding.</p>
          </list-item>
          <list-item>
            <p>Myopic choroidal neovascular membrane (CNV) is a common cause of visual impairment in patients with pathological myopia. The incidence of myopic CNV is estimated to be 10%, but it is even higher (35%) if the fellow eye was previously affected. Myopic CNV typically appears as a small, gray subretinal lesion beneath or near the fovea, and it may be associated with subretinal fluid or hemorrhage (see <bold>Image.</bold> Dome-Shaped Maculopathy With Subretinal Fluid). Fuchs spots are pigmented gray scars corresponding to regressed myopic CNV sites.</p>
          </list-item>
          <list-item>
            <p>Myopic tractional maculopathy results from vitreoretinal traction and its manifestations include retinoschisis, foveal retinal detachment, and lamellar or full-thickness macular hole.</p>
          </list-item>
          <list-item>
            <p>A dome-shaped macula is an inward bulge around the foveal region associated with scleral thickening; this is present in 20% of eyes with high myopia.<xref ref-type="bibr" rid="article-140075.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Structural anomalies and atrophy around the&#x000a0;optic nerve fibers and optic disc pits can result in visual field loss.<xref ref-type="bibr" rid="article-140075.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>Peripheral retinal holes or breaks are more possible findings.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-140075.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Spectral-domain optical coherence tomography (OCT) scanning is noninvasive, quick, and widely available. This scan is suitable for diagnosing and monitoring retinal pigment epithelium atrophy, myopic CNV, and myopic tractional maculopathy. OCT provides a regular measurement of retinal and choroidal thickness and subretinal or intraretinal fluid and also highlights the presence of macular holes, retinoschisis, or detachments. Dome-shaped maculopathy is best visualized on radial or vertical OCT slices (see <bold>Image.</bold> Dome-Shaped Maculopathy on Vertical Optical Coherence Tomography Scan).</p>
        <p>Fluorescein angiography provides detailed information about the type and activity of myopic CNV and helps plan treatment. Myopic CNV resembles the appearance of type 2 or classic CNV on fluorescein angiography, demonstrating early hyperfluorescence that increases in size and intensity through to the late phase. This can help differentiate between hemorrhage from a myopic CNV versus a lacquer crack, with the latter displaying blocked fluorescence instead of increasing hyperfluorescence&#x000a0;(see <bold>Image.&#x000a0;</bold>Fluorescein Angiogram Demonstrating Myopic Choroidal Neovascular Membrane). Other tests, such as OCT angiography, ultrasonography, magnetic resonance imaging, and Indocyanine Green Angiography, may be useful for evaluating the shape and perfusion of the retina and choroid. However, these tests are rarely used in a clinical setting.<xref ref-type="bibr" rid="article-140075.r15">[15]</xref><xref ref-type="bibr" rid="article-140075.r16">[16]</xref><xref ref-type="bibr" rid="article-140075.r17">[17]</xref></p>
      </sec>
      <sec id="article-140075.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Simple myopia can be satisfactorily corrected using refractive lenses (contact lenses, spectacles) or refractive surgery. Incentives to encourage outdoor play among children may help prevent myopia progression. Other methods include specialized contact lenses and low-dose topical atropine.<xref ref-type="bibr" rid="article-140075.r18">[18]</xref>&#x000a0;However, no proven therapy can reverse or halt the progressive retinal atrophy associated with pathological myopia.</p>
        <p>The mainstay treatment of myopic CNV is anti-vascular endothelial growth factors (VEGF) intravitreal injections. Results from large, randomized control trials have demonstrated superior visual and anatomical outcomes with anti-VEGF therapy compared to photodynamic therapy or control.<xref ref-type="bibr" rid="article-140075.r19">[19]</xref><xref ref-type="bibr" rid="article-140075.r20">[20]</xref> Fewer treatments with anti-VEGF therapy are needed for disease control compared with other subtypes of CNV (age-related macular degeneration).<xref ref-type="bibr" rid="article-140075.r19">[19]</xref></p>
        <p>The management of myopic tractional maculopathy remains debatable and depends on specific OCT findings.<xref ref-type="bibr" rid="article-140075.r21">[21]</xref>&#x000a0;Some clinicians favor a conservative approach as some cases remain stable or resolve following the release of retinal traction. However, those with pre-existing extensive macular retinoschisis may be more likely to progress and require intervention.<xref ref-type="bibr" rid="article-140075.r22">[22]</xref>&#x000a0;The surgical approaches consist of pars plana vitrectomy +/- internal limiting membrane peel versus a macular buckle procedure (see <bold>Image.&#x000a0;</bold>Myopic Macular Schisis).</p>
      </sec>
      <sec id="article-140075.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnoses for&#x000a0;degenerative myopia include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Age-related macular degeneration</p>
          </list-item>
          <list-item>
            <p>Choroidal rupture or angioid streaks may be mistaken for lacquer cracks</p>
          </list-item>
          <list-item>
            <p>Retinal pigment epithelial changes from previous central serous chorioretinopathy</p>
          </list-item>
          <list-item>
            <p>Ocular histoplasmosis</p>
          </list-item>
          <list-item>
            <p>Pattern dystrophies (eg, reticular dystrophy,&#x000a0;Doyne honeycomb retinal dystrophy)</p>
          </list-item>
        </list>
        <p>Other associated systemic disorders include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Developmental delay</p>
          </list-item>
          <list-item>
            <p>Prematurity</p>
          </list-item>
          <list-item>
            <p>Marfan syndrome</p>
          </list-item>
          <list-item>
            <p>Stickler syndrome</p>
          </list-item>
          <list-item>
            <p>Ehlers-Danlos syndrome</p>
          </list-item>
          <list-item>
            <p>Homocystinuria</p>
          </list-item>
          <list-item>
            <p>Down syndrome</p>
          </list-item>
          <list-item>
            <p>Noonan syndrome&#x000a0;<xref ref-type="bibr" rid="article-140075.r23">[23]</xref><xref ref-type="bibr" rid="article-140075.r24">[24]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-140075.s10" sec-type="Pertinent Studies and Ongoing Trials">
        <title>Pertinent Studies and Ongoing Trials</title>
        <p>The following trials&#x000a0;demonstrated that anti-VEGF therapy was effective for the treatment of myopic CNV, with good visual and anatomic benefits achieved with a limited number of injections:</p>
        <p>
<bold>RADIANCE </bold>
</p>
        <p>RADIANCE is&#x000a0;a&#x000a0;multicenter, randomized controlled study of ranibizumab in patients with secondary to pathologic myopia&#x000a0;(n= 277). This study compared intravitreal ranibizumab 0.5 mg to verteporfin photodynamic therapy to treat myopic CNV. The ranibizumab treatment group experienced a superior visual gain (14 letters vs 9 letters) at 12 months. Patients received a median of 2 treatments during the 12-month study period as guided by disease activity.<xref ref-type="bibr" rid="article-140075.r19">[19]</xref></p>
        <p>
<bold>MYRROR </bold>
</p>
        <p>MYRROR is a multicenter, randomized control trial of intravitreal aflibercept injection in patients with myopic&#x000a0;CNV (n= 122). This study compared intravitreal aflibercept 0.5 mg versus&#x000a0;placebo injection to treat myopic CNV. Additional injections were administered if there were signs of CNV activity during monthly visits. At week 24, the treatment group experienced superior visual gains (+12 letters vs -2 letters). Patients in the treatment group received a median of 2 injections in weeks 0&#x02013;8 and 0 injections in weeks 8&#x000a0;to 32.<xref ref-type="bibr" rid="article-140075.r20">[20]</xref></p>
      </sec>
      <sec id="article-140075.s11" sec-type="Treatment Planning ">
        <title>Treatment Planning </title>
        <p>The treatment regimen for a myopic choroidal neovascular membrane typically consists of intravitreal anti-VEGF injections. Often,&#x000a0;1 or&#x000a0;2 treatments spaced approximately four weeks apart are given, followed by monitoring and further treatment as needed if signs of choroidal neovascular activity such as subretinal fluid, hemorrhage, or leakage. Typical anti-VEGF agents and dosing is as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Bevacuzimab&#x000a0;(1.25 mg/0.05 mL)</p>
          </list-item>
          <list-item>
            <p>Aflibercept (2 mg/0.05 Ll)</p>
          </list-item>
          <list-item>
            <p>Ranibizumab (0.5 mg/0.05 mL)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-140075.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Pathologic myopia is a significant cause of vision loss worldwide. The prevalence of visual impairment secondary to&#x000a0;pathological myopia reaches as high as 0.5%, as seen in European and 1.4%&#x000a0;in Asian study results.<xref ref-type="bibr" rid="article-140075.r10">[10]</xref>&#x000a0;Long-term follow-up results from studies of patients diagnosed with myopic CNV report a mean decline in visual acuity, even despite adequate disease control on anti-VEGF therapy.<xref ref-type="bibr" rid="article-140075.r25">[25]</xref></p>
      </sec>
      <sec id="article-140075.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Patients with pathological myopia may experience a marked&#x000a0;drop in visual acuity secondary to a subretinal hemorrhage or myopic choroidal neovascular membrane. Despite prompt therapy, they can develop scarring and atrophy in the macula that&#x000a0;results in a permanent central scotoma; they also face an increased risk of early cataract formation, glaucoma, and retinal detachments, which can also lead to visual impairment.<xref ref-type="bibr" rid="article-140075.r26">[26]</xref></p>
      </sec>
      <sec id="article-140075.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients should be advised to attend their regular eye appointments to ensure their disease remains optimally controlled by the available treatments. Any sudden changes to vision, including metamorphopsia, scotoma, flashes, floaters, or blurry vision, should prompt an urgent assessment by an eye care professional. Patients should be advised to check each eye with an Amsler grid regularly.</p>
      </sec>
      <sec id="article-140075.s15" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Despite the lack of formal guidelines, a collaborative care approach towards myopia prevention, detection, and management is required. Given the rising prevalence of myopia, which develops from childhood, public health needs to advocate for policies that encourage outdoor activity. Screening for myopia in schools or other forums requires a team of individuals, such as trained technicians or nurses, and a system in place for referral to an eye care provider for evaluation. Ophthalmologists and optometrists manage treatment decisions such as the initiation of pharmacological or optical therapy to halt myopic progression.</p>
        <p>Additionally, optometrists and ophthalmologists play an important role in screening for pathological myopia and its associated complications. Collaboration between glaucoma, vitreoretinal, and medical retinal specialists ensures patients receive specialized care when necessary. Occupational therapists and optometrists specializing in low vision play an important role in visual rehabilitation, helping individuals maintain an independent living and maximize their vision when it is limited due to their disease.</p>
      </sec>
      <sec id="article-140075.s16">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=140075&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=140075">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/eye-health/degenerative-myopia-nearsightedness/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=140075">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/140075/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=140075">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-140075.s17">
        <fig id="article-140075.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Dome-Shaped Maculopathy With Subretinal Fluid. Myopic choroidal neovascular membranes typically appear as a small, gray subretinal lesion beneath or near the fovea, and it may be associated with subretinal fluid or hemorrhage. Contributed by A Yap, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Dome" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-140075.s18">
        <fig id="article-140075.image.f2" position="float" orientation="portrait">
          <caption>
            <p>Dome-Shaped Maculopathy on Vertical Optical Coherence Tomography Scan. Dome-shaped maculopathy is best visualized on radial or vertical optical coherence tomography slices. Contributed by A Yap, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Dome2" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-140075.s19">
        <fig id="article-140075.image.f3" position="float" orientation="portrait">
          <caption>
            <p>Fluorescein Angiogram Demonstrating Myopic Choroidal Neovascular Membrane. Fluorescein angiograms can help differentiate between hemorrhage from a myopic choroidal neovascular membrane versus a lacquer crack, with the latter displaying blocked fluorescence instead of increasing hyperfluorescence. Contributed by A Yap, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="FA" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-140075.s20">
        <fig id="article-140075.image.f4" position="float" orientation="portrait">
          <caption>
            <p>Myopic Macular Schisis. Surgical approaches for this condition consist of pars plana vitrectomy +/- internal limiting membrane peel versus a macular buckle procedure. Contributed by A Yap, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Macular__schisis" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <floats-group id="article-140075.s21">
        <fig id="article-140075.image.f5" position="float" orientation="portrait">
          <caption>
            <p>Grade 3 Pathological Myopia With Diffuse Chorioretinal Atrophy. This image shows grade 3 pathological myopia with excessive axial elongation stretches and retina, choroid, and sclera thinning. Contributed by A Yap, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Grade__3__myopia" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-140075.s22">
        <title>References</title>
        <ref id="article-140075.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fredrick</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Myopia.</article-title>
            <source>BMJ</source>
            <year>2002</year>
            <month>May</month>
            <day>18</day>
            <volume>324</volume>
            <issue>7347</issue>
            <fpage>1195</fpage>
            <page-range>1195-9</page-range>
            <pub-id pub-id-type="pmid">12016188</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140075.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ohno-Matsui</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kawasaki</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jonas</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Cheung</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Saw</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Verhoeven</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Klaver</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Moriyama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shinohara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kawasaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yamazaki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Meuer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ishibashi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Yasuda</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yamashita</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sugano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>TY</given-names>
              </name>
              <collab>META-analysis for Pathologic Myopia (META-PM) Study Group</collab>
            </person-group>
            <article-title>International photographic classification and grading system for myopic maculopathy.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2015</year>
            <month>May</month>
            <volume>159</volume>
            <issue>5</issue>
            <fpage>877</fpage>
            <page-range>877-83.e7</page-range>
            <pub-id pub-id-type="pmid">25634530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140075.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guggenheim</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Kirov</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hodson</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>The heritability of high myopia: a reanalysis of Goldschmidt's data.</article-title>
            <source>J Med Genet</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>227</fpage>
            <page-range>227-31</page-range>
            <pub-id pub-id-type="pmid">10777361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140075.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cai</surname>
                <given-names>XB</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>ZB</given-names>
              </name>
            </person-group>
            <article-title>An overview of myopia genetics.</article-title>
            <source>Exp Eye Res</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>188</volume>
            <fpage>107778</fpage>
            <pub-id pub-id-type="pmid">31472110</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140075.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rose</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>IG</given-names>
              </name>
              <name>
                <surname>Ip</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kifley</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Huynh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Outdoor activity reduces the prevalence of myopia in children.</article-title>
            <source>Ophthalmology</source>
            <year>2008</year>
            <month>Aug</month>
            <volume>115</volume>
            <issue>8</issue>
            <fpage>1279</fpage>
            <page-range>1279-85</page-range>
            <pub-id pub-id-type="pmid">18294691</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140075.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morgan</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Rose</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>How genetic is school myopia?</article-title>
            <source>Prog Retin Eye Res</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-38</page-range>
            <pub-id pub-id-type="pmid">15555525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140075.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wallman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Winawer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Homeostasis of eye growth and the question of myopia.</article-title>
            <source>Neuron</source>
            <year>2004</year>
            <month>Aug</month>
            <day>19</day>
            <volume>43</volume>
            <issue>4</issue>
            <fpage>447</fpage>
            <page-range>447-68</page-range>
            <pub-id pub-id-type="pmid">15312645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140075.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Morgan</surname>
                <given-names>IG</given-names>
              </name>
              <name>
                <surname>Ohno-Matsui</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Saw</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Myopia.</article-title>
            <source>Lancet</source>
            <year>2012</year>
            <month>May</month>
            <day>05</day>
            <volume>379</volume>
            <issue>9827</issue>
            <fpage>1739</fpage>
            <page-range>1739-48</page-range>
            <pub-id pub-id-type="pmid">22559900</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140075.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holden</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Fricke</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Jong</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Naidoo</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Sankaridurg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Naduvilath</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Resnikoff</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050.</article-title>
            <source>Ophthalmology</source>
            <year>2016</year>
            <month>May</month>
            <volume>123</volume>
            <issue>5</issue>
            <fpage>1036</fpage>
            <page-range>1036-42</page-range>
            <pub-id pub-id-type="pmid">26875007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140075.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Ferreira</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hughes</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Carter</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2014</year>
            <month>Jan</month>
            <volume>157</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-25.e12</page-range>
            <pub-id pub-id-type="pmid">24099276</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140075.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gordon</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Donzis</surname>
                <given-names>PB</given-names>
              </name>
            </person-group>
            <article-title>Refractive development of the human eye.</article-title>
            <source>Arch Ophthalmol</source>
            <year>1985</year>
            <month>Jun</month>
            <volume>103</volume>
            <issue>6</issue>
            <fpage>785</fpage>
            <page-range>785-9</page-range>
            <pub-id pub-id-type="pmid">4004614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140075.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Curtin</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>The posterior staphyloma of pathologic myopia.</article-title>
            <source>Trans Am Ophthalmol Soc</source>
            <year>1977</year>
            <volume>75</volume>
            <fpage>67</fpage>
            <page-range>67-86</page-range>
            <pub-id pub-id-type="pmid">613534</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140075.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liang</surname>
                <given-names>IC</given-names>
              </name>
              <name>
                <surname>Shimada</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Nagaoka</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Moriyama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ohno-Matsui</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Clinical Features in Highly Myopic Eyes with and without a Dome-Shaped Macula.</article-title>
            <source>Ophthalmology</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>122</volume>
            <issue>8</issue>
            <fpage>1591</fpage>
            <page-range>1591-600</page-range>
            <pub-id pub-id-type="pmid">25986898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140075.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ohno-Matsui</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shimada</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yasuzumi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kojima</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moriyama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tokoro</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Long-term development of significant visual field defects in highly myopic eyes.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>152</volume>
            <issue>2</issue>
            <fpage>256</fpage>
            <page-range>256-265.e1</page-range>
            <pub-id pub-id-type="pmid">21664594</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140075.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vaghefi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kauv</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Pan</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Squirrell</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Application of Arterial Spin Labelling in Detecting Retinal Ischemia.</article-title>
            <source>Case Rep Ophthalmol</source>
            <year>2017</year>
            <season>Sep-Dec</season>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>545</fpage>
            <page-range>545-557</page-range>
            <pub-id pub-id-type="pmid">29422857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140075.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Sheikh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Phasukkijwatana</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dolz-Marco</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rahimi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iafe</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Freund</surname>
                <given-names>KB</given-names>
              </name>
              <name>
                <surname>Sadda</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Sarraf</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Quantitative OCT Angiography of the Retinal Microvasculature and the Choriocapillaris in Myopic Eyes.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2017</year>
            <month>Apr</month>
            <day>01</day>
            <volume>58</volume>
            <issue>4</issue>
            <fpage>2063</fpage>
            <page-range>2063-2069</page-range>
            <pub-id pub-id-type="pmid">28388703</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140075.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moriyama</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ohno-Matsui</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hayashi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shimada</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tokoro</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Morita</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Topographic analyses of shape of eyes with pathologic myopia by high-resolution three-dimensional magnetic resonance imaging.</article-title>
            <source>Ophthalmology</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>118</volume>
            <issue>8</issue>
            <fpage>1626</fpage>
            <page-range>1626-37</page-range>
            <pub-id pub-id-type="pmid">21529960</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140075.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baird</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Saw</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Lanca</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Guggenheim</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Smith Iii</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Matsui</surname>
                <given-names>KO</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Sankaridurg</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Chia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rosman</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lamoureux</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Man</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Myopia.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2020</year>
            <month>Dec</month>
            <day>17</day>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>99</fpage>
            <pub-id pub-id-type="pmid">33328468</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140075.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wolf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Balciuniene</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Laganovska</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Menchini</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Ohno-Matsui</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Silva</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pilz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gekkieva</surname>
                <given-names>M</given-names>
              </name>
              <collab>RADIANCE Study&#x000a0;Group</collab>
            </person-group>
            <article-title>RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia.</article-title>
            <source>Ophthalmology</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>121</volume>
            <issue>3</issue>
            <fpage>682</fpage>
            <page-range>682-92.e2</page-range>
            <pub-id pub-id-type="pmid">24326106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140075.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ikuno</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ohno-Matsui</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Korobelnik</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Vitti</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Stemper</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Asmus</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Zeitz</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ishibashi</surname>
                <given-names>T</given-names>
              </name>
              <collab>MYRROR Investigators</collab>
            </person-group>
            <article-title>Intravitreal Aflibercept Injection in Patients with Myopic Choroidal Neovascularization: The MYRROR Study.</article-title>
            <source>Ophthalmology</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>122</volume>
            <issue>6</issue>
            <fpage>1220</fpage>
            <page-range>1220-7</page-range>
            <pub-id pub-id-type="pmid">25745875</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140075.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Frisina</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gius</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Palmieri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Finzi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tozzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Parolini</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Myopic Traction Maculopathy: Diagnostic and Management Strategies.</article-title>
            <source>Clin Ophthalmol</source>
            <year>2020</year>
            <volume>14</volume>
            <fpage>3699</fpage>
            <page-range>3699-3708</page-range>
            <pub-id pub-id-type="pmid">33173268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140075.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shimada</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tokoro</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ohno-Matsui</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Natural course of myopic traction maculopathy and factors associated with progression or resolution.</article-title>
            <source>Am J Ophthalmol</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>156</volume>
            <issue>5</issue>
            <fpage>948</fpage>
            <page-range>948-957.e1</page-range>
            <pub-id pub-id-type="pmid">23972301</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140075.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mrugacz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rydzanicz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Frajdenberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Podfigurna-Musielak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gajecka</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Myopia in systemic disorders].</article-title>
            <source>Klin Oczna</source>
            <year>2009</year>
            <volume>111</volume>
            <issue>1-3</issue>
            <fpage>84</fpage>
            <page-range>84-8</page-range>
            <pub-id pub-id-type="pmid">19517854</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140075.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marr</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Halliwell-Ewen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Soler</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ainsworth</surname>
                <given-names>JR</given-names>
              </name>
            </person-group>
            <article-title>Associations of high myopia in childhood.</article-title>
            <source>Eye (Lond)</source>
            <year>2001</year>
            <month>Feb</month>
            <volume>15</volume>
            <issue>Pt 1</issue>
            <fpage>70</fpage>
            <page-range>70-4</page-range>
            <pub-id pub-id-type="pmid">11318301</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140075.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cheung</surname>
                <given-names>CMG</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Holz</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Lai</surname>
                <given-names>TYY</given-names>
              </name>
              <name>
                <surname>Larsen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mitchell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ohno-Matsui</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Wolf</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>TY</given-names>
              </name>
            </person-group>
            <article-title>Myopic Choroidal Neovascularization: Review, Guidance, and Consensus Statement on Management.</article-title>
            <source>Ophthalmology</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>124</volume>
            <issue>11</issue>
            <fpage>1690</fpage>
            <page-range>1690-1711</page-range>
            <pub-id pub-id-type="pmid">28655539</pub-id>
          </element-citation>
        </ref>
        <ref id="article-140075.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitchell</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hourihan</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sandbach</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>The relationship between glaucoma and myopia: the Blue Mountains Eye Study.</article-title>
            <source>Ophthalmology</source>
            <year>1999</year>
            <month>Oct</month>
            <volume>106</volume>
            <issue>10</issue>
            <fpage>2010</fpage>
            <page-range>2010-5</page-range>
            <pub-id pub-id-type="pmid">10519600</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
